Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2733235 | 0.83 | POLB (0.42) | HDAC3HDAC1HDAC2HDAC6MAPT | |
| SCHEMBL4577905 | 0.80 | ALDH1A1 (0.35) | HDAC3HDAC1HDAC2HDAC6MAPT | |
| SCHEMBL4577910 | 0.76 | ALDH1A1 (0.35) | HDAC3HDAC1HDAC2HDAC6MAPT | |
| SCHEMBL12259749 | 0.73 | — | — | |
| SCHEMBL19918802 | 0.71 | — | — | |
| SCHEMBL11985623 | 0.70 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL23571957 | 0.70 | TSHR (0.41) | MAPTLMNAALDH1A1POLB | |
| SCHEMBL27420042 | 0.69 | POLB (0.38) | HDAC3HDAC1HDAC2HDAC6MAPT | |
| SCHEMBL4823707 | 0.68 | POLB (0.36) | HDAC3HDAC1HDAC2HDAC6MAPT | |
| SCHEMBL15125093 | 0.68 | ALDH1A1 (0.39) | MAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | MCL1, ABL1, MALT1 | HDAC3 102/4885HDAC1 91/4885HDAC2 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.